Selected Adverse Reactions in cSSSI

  • The most clinically significant adverse reactions observed with CUBICIN® (daptomycin for injection) 4 mg/kg (cSSSI trials) and 6 mg/kg (S. aureus bacteremia/endocarditis trial) were abnormal liver function tests, elevated CPK, and dyspnea

Incidence of adverse reactions that occurred in 2% of patients in the CUBICIN treatment group and ≥ the comparator treatment group in Phase 3 cSSSI trials

Event PERCENTAGE OF PATIENTS (%)
CUBICIN (n=534) Comparatora (n=558)
Diarrhea 5.2 4.3
Headache 5.4 5.4
Dizziness 2.2 2.0
Rash 4.3 3.8
Abnormal LFT 3.0 1.6
Elevated CPK 2.8 1.8
Urinary tract infection 2.4 0.5
Hypotension 2.4 1.4
Dyspnea 2.1 1.6
  1. Vancomycin or semisynthetic penicillin.

Learn about the mechanism of action of CUBICIN® (daptomycin for injection). »